We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GEHC Unifies bkActiv With Stealth AXiS for Live Neurosurgery Imaging
Read MoreHide Full Article
Key Takeaways
GEHC integrates bkActiv ultrasound with Medtronic's Stealth AXiS for real-time cranial surgery imaging.
GEHC solution enables live visualization to address brain shift and improve surgical navigation accuracy.
GEHC expands reach and recurring revenue potential via deeper Medtronic partnership and ecosystem integration.
GE HealthCare Technologies Inc. (GEHC - Free Report) recently announced a digital integration between its bkActiv intraoperative ultrasound (iUS) system and Medtronic’s (MDT - Free Report) Stealth AXiS surgical navigation system. Now commercially available, this combined solution delivers real-time advanced imaging during cranial surgeries, enhancing surgical planning and navigation workflows.
The companies are set to showcase this advancement at the American Association of Neurological Surgeons Annual Scientific Meeting in May 2026, offering clinicians a closer look at how real-time imaging and navigation can transform surgical decision-making.
Per management, real-time visualization plays a vital role in helping cranial surgical teams evaluate anatomy, adapt to changes and make informed decisions during procedures. The company is pleased to deepen its longstanding partnership with Medtronic by integrating bkActiv with the Stealth AXiS system, reinforcing its shared commitment to enhancing surgical accuracy and boosting clinician confidence.
Likely Trend of GEHC Stock Following the News
Following the announcement, shares of GEHC dropped 1.1% at yesterday’s closing. In the year-to-date period, shares of the company have lost 11.2% compared with the industry’s 14.2% decline and the S&P 500’s 0.6% fall.
In the long run, the integration strengthens GEHC’s competitive positioning in the surgical imaging and navigation market. By embedding its ultrasound technology within Medtronic’s navigation ecosystem, GEHC expands its enterprise reach, increases the stickiness of its solutions and enhances opportunities for recurring revenues. The collaboration also reinforces GE HealthCare’s ability to deliver integrated, real-time imaging solutions, supporting sustained growth in its Surgical Innovations segment.
GEHC currently has a market capitalization of $33.65 billion.
Image Source: Zacks Investment Research
More on the Digital Integration
At its core, the integration enables neurosurgeons to use bkActiv as a seamless, “plug-and-play” visualization tool within the Stealth AXiS system, without interrupting existing surgical workflows. Recently cleared by the FDA for cranial procedures in the United States, the Stealth AXiS platform combines surgical planning, navigation and robotics into a unified system, enabling real-time insights in the operating room.
One of the most valuable applications of this integration is addressing “brain shift,” a natural movement or deformation of the brain that reduces the accuracy of pre-operative images. The bkActiv system is designed to deliver real-time visualization, helping clinicians monitor anatomical changes by providing live intraoperative ultrasound (iUS) images to the Stealth AXiS navigation system, where they can be viewed alongside pre-surgical MRI or CT scans.
Beyond integration, bkActiv brings a suite of advanced features designed for the neurosurgical environment. These include an image mirror function that replicates the ultrasound display on the scanner’s glass interface, incorporates sensitive color Doppler technology to visualize blood flow, along with advanced algorithms that ensure consistent image resolution and clarity around targeted areas.
In addition, bkActiv offers fully immersible transducers for simplified sterilization and single-use needle guides for improved safety. Its Transducer Smart Button technology enables surgeons to freeze, store and print images with a single press, while a sterilizable remote control allows full operation of the scanner from the sterile field.
Industry Prospects Favoring the Market
Going by the data provided by Persistence Market Research, the intraoperative imaging market is valued at $2.9 billion in 2026 and is expected to witness a CAGR of 6.1% through 2033.
Factors like the adoption of advanced imaging systems, integration of AI for surgical precision and workflow efficiency, strategic collaborations and system integration are boosting the market’s growth.
Other News
GE HealthCare recently obtained FDA 510(k) clearance for True Definition DL, its newest deep learning-based CT image reconstruction solution. The technology delivers highly detailed, sharp images and builds on TrueFidelity DL and True Enhance DL, enabling faster scans and enhanced imaging performance across pulmonary, musculoskeletal and inner ear applications.
GE HealthCare has secured FDA 510(k) clearance for Photonova Spectra, a next-generation photon-counting CT solution. Built on advanced Deep Silicon detector technology, the platform offers flexible configurations to suit varied clinical needs. It combines wide coverage with ultra-high-definition spatial and spectral imaging, enabling faster scan speeds and accurate visualization of subtle tissue differences, small lesions and vascular structures.
GE HealthCare announced that View, a next-generation diagnostic imaging viewer within its Genesis Radiology Workspace, has received 510(k) clearance from the FDA. Positioned as a zero-footprint viewer and cloud-native solution, the platform allows radiologists to access diagnostic images directly through a web browser without the need for specialized on-site hardware or software installations.
Some other top-ranked stocks from the broader medical space are Pacific Biosciences of California (PACB - Free Report) and Phibro Animal Health (PAHC - Free Report) .
Pacific Biosciences of California, currently sporting a Zacks Rank #1 (Strong Buy), reported a fourth-quarter 2025 adjusted loss of 12 cents per share, which surpassed the Zacks Consensus Estimate by 36.8%. Revenues of $44.6 million beat the Zacks Consensus Estimate by 9.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PACB has an estimated earnings recession rate of 1.9% compared with the industry’s 14.1% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 27.7%.
Phibro Animal Health, currently carrying a Zacks Rank #2, reported second-quarter fiscal 2026 adjusted earnings per share (EPS) of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Shutterstock
GEHC Unifies bkActiv With Stealth AXiS for Live Neurosurgery Imaging
Key Takeaways
GE HealthCare Technologies Inc. (GEHC - Free Report) recently announced a digital integration between its bkActiv intraoperative ultrasound (iUS) system and Medtronic’s (MDT - Free Report) Stealth AXiS surgical navigation system. Now commercially available, this combined solution delivers real-time advanced imaging during cranial surgeries, enhancing surgical planning and navigation workflows.
The companies are set to showcase this advancement at the American Association of Neurological Surgeons Annual Scientific Meeting in May 2026, offering clinicians a closer look at how real-time imaging and navigation can transform surgical decision-making.
Per management, real-time visualization plays a vital role in helping cranial surgical teams evaluate anatomy, adapt to changes and make informed decisions during procedures. The company is pleased to deepen its longstanding partnership with Medtronic by integrating bkActiv with the Stealth AXiS system, reinforcing its shared commitment to enhancing surgical accuracy and boosting clinician confidence.
Likely Trend of GEHC Stock Following the News
Following the announcement, shares of GEHC dropped 1.1% at yesterday’s closing. In the year-to-date period, shares of the company have lost 11.2% compared with the industry’s 14.2% decline and the S&P 500’s 0.6% fall.
In the long run, the integration strengthens GEHC’s competitive positioning in the surgical imaging and navigation market. By embedding its ultrasound technology within Medtronic’s navigation ecosystem, GEHC expands its enterprise reach, increases the stickiness of its solutions and enhances opportunities for recurring revenues. The collaboration also reinforces GE HealthCare’s ability to deliver integrated, real-time imaging solutions, supporting sustained growth in its Surgical Innovations segment.
GEHC currently has a market capitalization of $33.65 billion.
Image Source: Zacks Investment Research
More on the Digital Integration
At its core, the integration enables neurosurgeons to use bkActiv as a seamless, “plug-and-play” visualization tool within the Stealth AXiS system, without interrupting existing surgical workflows. Recently cleared by the FDA for cranial procedures in the United States, the Stealth AXiS platform combines surgical planning, navigation and robotics into a unified system, enabling real-time insights in the operating room.
One of the most valuable applications of this integration is addressing “brain shift,” a natural movement or deformation of the brain that reduces the accuracy of pre-operative images. The bkActiv system is designed to deliver real-time visualization, helping clinicians monitor anatomical changes by providing live intraoperative ultrasound (iUS) images to the Stealth AXiS navigation system, where they can be viewed alongside pre-surgical MRI or CT scans.
Beyond integration, bkActiv brings a suite of advanced features designed for the neurosurgical environment. These include an image mirror function that replicates the ultrasound display on the scanner’s glass interface, incorporates sensitive color Doppler technology to visualize blood flow, along with advanced algorithms that ensure consistent image resolution and clarity around targeted areas.
In addition, bkActiv offers fully immersible transducers for simplified sterilization and single-use needle guides for improved safety. Its Transducer Smart Button technology enables surgeons to freeze, store and print images with a single press, while a sterilizable remote control allows full operation of the scanner from the sterile field.
Industry Prospects Favoring the Market
Going by the data provided by Persistence Market Research, the intraoperative imaging market is valued at $2.9 billion in 2026 and is expected to witness a CAGR of 6.1% through 2033.
Factors like the adoption of advanced imaging systems, integration of AI for surgical precision and workflow efficiency, strategic collaborations and system integration are boosting the market’s growth.
Other News
GE HealthCare recently obtained FDA 510(k) clearance for True Definition DL, its newest deep learning-based CT image reconstruction solution. The technology delivers highly detailed, sharp images and builds on TrueFidelity DL and True Enhance DL, enabling faster scans and enhanced imaging performance across pulmonary, musculoskeletal and inner ear applications.
GE HealthCare has secured FDA 510(k) clearance for Photonova Spectra, a next-generation photon-counting CT solution. Built on advanced Deep Silicon detector technology, the platform offers flexible configurations to suit varied clinical needs. It combines wide coverage with ultra-high-definition spatial and spectral imaging, enabling faster scan speeds and accurate visualization of subtle tissue differences, small lesions and vascular structures.
GE HealthCare announced that View, a next-generation diagnostic imaging viewer within its Genesis Radiology Workspace, has received 510(k) clearance from the FDA. Positioned as a zero-footprint viewer and cloud-native solution, the platform allows radiologists to access diagnostic images directly through a web browser without the need for specialized on-site hardware or software installations.
GE HealthCare Technologies Inc. Price
GE HealthCare Technologies Inc. price | GE HealthCare Technologies Inc. Quote
GEHC’s Zacks Rank & Other Key Picks
Currently, GEHC has a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are Pacific Biosciences of California (PACB - Free Report) and Phibro Animal Health (PAHC - Free Report) .
Pacific Biosciences of California, currently sporting a Zacks Rank #1 (Strong Buy), reported a fourth-quarter 2025 adjusted loss of 12 cents per share, which surpassed the Zacks Consensus Estimate by 36.8%. Revenues of $44.6 million beat the Zacks Consensus Estimate by 9.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PACB has an estimated earnings recession rate of 1.9% compared with the industry’s 14.1% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 27.7%.
Phibro Animal Health, currently carrying a Zacks Rank #2, reported second-quarter fiscal 2026 adjusted earnings per share (EPS) of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.